TIGERTRIEVER (TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic ...
NEW ORLEANS -- Loberamisal improved functional outcomes after acute ischemic stroke in a placebo-controlled phase III trial, ...
Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...
With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.
A fault in J&J MedTech’s CEREPAK detachable coils, used in intracranial aneurysm embolisation procedures, has been associated ...
MHRA's Chief Safety Officer, Dr Alison Cave issued new guidance on how to respond if your vision becomes affected by weight ...
For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...
The AHA/American Stroke Association released updated recommendations for early management of patients with acute ischemic stroke.
Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health ...
An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...
Clinical Trials Arena on MSN
Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer presented the data from OCEANIC-STROKE at the International Stroke Conference 2026 in New Orleans.
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results